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Available online 28 June 2012Abstract Maturation of induced pluripotent stem cells (hiPSCs) to hepatocyte-like cells (HLCs) has been proposed to address
the shortage of human hepatocytes for therapeutic applications. The purpose of this study was to evaluate hiPSCs, HLCs and
hepatocytes, all of human origin, in terms of performance metrics of relevance to cell therapies. hiPSCs were differentiated to
HLCs in vitro using an established four-stage approach. We observed that hiPSCs had low oxygen consumption and possessed
small, immature mitochondria located around the nucleus. With maturation to HLCs, mitochondria showed characteristic
changes inmorphology, ultrastructure, and gene expression. These changes inmitochondria included elongatedmorphology, swollen
cristae, dense matrices, cytoplasmic migration, increased expression of mitochondrial DNA transcription and replication-related
genes, and increased oxygen consumption. Following differentiation, HLCs expressed characteristic hepatocyte proteins including
albumin and hepatocyte nuclear factor 4-alpha, and intrinsic functions including cytochrome P450 metabolism. But HLCs also
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197Human Hepatocyte-Like Cells for Cell TherapyFurthermore, the levels of albumin production, urea production, cytochrome P450 activity, andmitochondrial function of HLCs were
significantly lower than primary human hepatocytes.
Conclusion- hiPSCs offer an unlimited source of human HLCs. However, reduced functionality of HLCs compared to primary
human hepatocytes limits their usefulness in clinical practice. Novel techniques are needed to complete differentiation of
hiPSCs to mature hepatocytes.
© 2012 Elsevier B.V. All rights reserved.Contents
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Liver transplantation is a successful treatment for patients
with end-stage liver disease. However, transplantable donor
livers are in short supply. Hepatocyte transplantation and
bioartificial liver (BAL) devices have been proposed as thera-
peutic alternatives to the shortage of transplantable livers. BAL
is an extracorporeal supportive therapy developed to bridge
patients with liver failure to liver transplantation or to recovery
of the native liver. Hepatocyte transplantation is best suited for
patients with metabolic liver disease for which smaller number
of cells (b10% of liver mass) may be curative. Both BAL and
hepatocyte transplantation are cellular therapies that avoid use
of a whole liver.
Though once controversial, it is now well accepted that
hepatocytes can be derived from progenitor cells which include
pluripotent stem cells, either embryonic or native to the liver or
in blood (Basma et al., 2009; Wang et al., 2011). Furthermore,
techniques now exist for production of human induced
pluripotent stem cells (hiPSCs) from somatic cells (Yu et al.,
2007). Therefore, in theory, hiPSCs could provide an unlimitedsource of human hepatocytes for BAL therapy and cell
transplantation. Preliminary reports indicate that human
hepatocyte-like cells (HLCs) can be derived from hiPSCs under
in vitro conditions (Si-Tayeb et al., 2010). These findings are
exciting since they suggest the possibility of producing HLCs
from the patient's own cells and cell transplantation without
immunosuppression.
The HLCs derived from hiPSCs express characteristic
hepatocyte proteins including alpha-1-antitrypsin, albumin
(Alb), and hepatocyte nuclear factor 4-alpha (HNF4α). They
also display intrinsic hepatocyte functions including cyto-
chrome P450 (CYP) metabolism. The efficiency of induced
pluripotent stem cells (iPSCs) directed-differentiation into
HLCs is variable. Some protocols describe over 80% differ-
entiation efficiency, but none yet achieve complete differ-
entiation of hiPSCs into hepatocytes. Transplantation of
undifferentiated iPSCs in immunodeficient recipients results
in the formation of teratomas. However, the risks and benefits
of transplantation of iPSCs into immunocompetent recipients
are poorly studied. Reports of BAL therapy using HLCs derived
from hiPSCs do not yet exist.
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tion status and functionality of three human cell types (hiPSCs,
HLCs and primary hepatocytes) under in vitro conditions with
regards to their usefulness in human cell therapy. Function-
ality and differentiation of these three cell types were judged
by liver-specific biochemical activities including the urea
cycle, mitochondrial maturation including ultrastructure, and
liver-related gene expression.
Experimental procedures
Feeder-free iPSCs culture conditions
Human iPSCs were generated from human cardiac fibroblasts
(HCFs) as previously described (Thatava et al., 2011). Briefly,
1×105 HCFs (ScienCell Research Laboratories, Carlsbad, CA,
USA; no. 6300) were seeded 1 day before infection in each
well of six-well plates with Dulbecco's modified Eagle's
medium (DMEM) containing 10% FBS, penicillin (100 U/mL)
and streptomycin (100 mg/mL) (complete DMEM), and trans-
duced with pluripotency factor-expressing lentiviral vectors
(octamer-binding transcription factor 4 (OCT4), SOX2, KLF4,
c-MYC). Putative hiPSCs colonies were observed 1 to 2 weeks
after vector transduction. Clones of hiPSCs were picked based
on morphology and size. A suitable clone (HCF#1 hiPSCs) was
selected. This clone was maintained on tissue culture plates
coated with Matrigel (BD Biosciences, San Jose, CA, USA;
no. 354277) in feeder-free medium (HEScGRO [Millipore, no
SCM020] supplemented with 20% mTeSR1 complete medium
[STEMCELL Technologies Inc., Vancouver, BC, Canada; no.
05850]) under a mix of 5% CO2/ambient air.
In vitro differentiation of hiPSCs to HLCs
HLCs were produced by differentiation of HCF#1 hiPSCs in
vitro using an established 4-stage approach (Si-Tayeb et al.,
2010) with minor modifications: Stage 1 (S1)—endoderm
induction, Stage 2 (S2)—hepatic specification, Stage 3 (S3)—
hepatoblast expansion and Stage 4 (S4)—hepatic maturation.
Briefly, endoderm differentiation was initiated by removing
feeder-free medium and exposing 70% confluent cultures of
HCF#1 hiPSCs to RPMI1640 media containing B27 Supplements
Minus Insulin (Invitrogen, 0050129-SA), 100 ng/mL Activin A
(R&D Systems, 338-AC-050/CF), 10 ng/ml bone morphogenetic
protein 4 (BMP4) (Peprotech) and 20 ng/ml fibroblast growth
factor 2 (FGF2) (Invitrogen, PHG0024). After 8 days of culture
in 5% CO2 with ambient oxygen, culture dishes containing
induced definitive endoderm were moved to 5%CO2/4%O2 in
RPMI/B27 Supplements (Invitrogen, 0080085-SA) medium
supplemented with 20 ng/mL BMP4 and 10 ng/mL FGF2 for
5 days. We then cultured the specified hepatic cells in RPMI/
B27 supplemented with 20 ng/mL hepatocyte growth factor
(HGF, Peprotech), under 5% CO2/4%O2 for 5 days. For the final
stage of differentiation, cultures were transferred to 5%
CO2/ambient O2, and the media were replaced with HCM™
hepatocyte culture medium (Lonza, Walkersville, MD USA,
CC-3198 but omitting the EGF) supplemented with 20 ng/mL
Oncostatin M (R&D Systems, 295-OM-010/CF) for an additional
5 days. In summary, cell-types were selected as follows:
hiPSCs (day 0), S1—endoderm (day 8), S2—specified hepatic
(day 13), S3—hepatoblast (day 18), and S4—HLCs (day 23).Primary hepatocytes
The human hepatocytes were purchased from Yecuris Corpo-
ration. These primary human hepatocytes were produced by
robust in vivo expansion in genetically engineeredmice (Azuma
et al., 2010). Human hepatocytes were cultured in collagen IV
coated plates with William's E medium.
Immunofluorescence
For immunocytochemistry, cultured cells were fixed with 4%
paraformaldehyde for 30 min at room temperature, washed
with phosphate-buffered saline (PBS) three times for 5 min
each, and permeabilized with 0.5% Triton X-100 (Sigma) in
PBS for 15 min, and blocked with 3% BSA in PBS for 15 min.
Cells were incubated overnight at 4 °C with primary anti-
bodies diluted in 1% BSA in PBS. Primary antibodies included
OCT4 (Santa Cruz Biotechnology Inc., CA, #sc-9081), GATA4
(Santa Cruz, #sc-1237), HNF4α (Santa Cruz, #sc-6556), alpha
fetoprotein (AFP) (Sigma-Aldrich, #A8452), and albumin
(Bethy Laboratories Inc. A80-129A). Antigens were visual-
ized using secondary antibodies conjugated with either
Alexa 488 or Alexa 568 (Invitrogen, #A11057, A11055, A21202,
A21206).
Periodic acid-schiff (PAS) staining
PAS staining was performed on the last day of S4, using a
commercial staining kit (Sigma-Aldrich, #395) according to
the manufacturer's instructions.
Quantitative reverse transcription polymerase
chain reaction (QRT-PCR)
Total RNA was extracted from cultured cells at each time
point using an RNeasy Plus MiniKit (Qiagen, Valencia, CA)
according to the manufacturer's instructions. All PCR were
performed in 96-well optical reaction plates (Applied
BioSystems, Foster City, CA) in 20 μL reaction volume using
SYBR Green PCR Master Mix (Applied Biosystems, No.
4389986). Reactions were carried out on the ABI PRISM®
7900HT Sequence Detection System (SDS) (Applied Biosys-
tems) and data were analyzed with the SDS Version 2.4
software. Triplicate amplifications were carried out for each
target gene. Quantification was performed using the com-
parative Ct method normalized with the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Ex-
pression of each target gene at each stage of differentiation
was normalized to its level in hiPSCs (day 0). For expression of
genes that could not be detected in hiPSCs, we used expression




Cells for mitochondria labeling were washed twice with PBS
and incubated at 37 °C for 20 min in 50 nM mitochondrion-
selective dye MitoTracker Red CMXRos (Molecular Probes Inc.,
#M7512). Nuclei were stained with DAPI. Staining solution was
Table 1 Primer sequences for RT-PCR.
Genes Abbr. 5′→3′ Product size
(bp)
Alpha fetoprotein AFP Forward: AGCTTGGTGGTGGATGAAAC 248
Reverse: CCCTCTTCAGCAAAGCAGAC
Albumin Alb Forward: GCACAGAATCCTTGGTGAACAG 101
Reverse: ATGGAAGGTGAATGTTTCAGCA
Arginase 1 Arg1 Forward: GCAGAAGTCAAGAAGAACGG 153
Reverse: GGTTGTCAGTGGAGTGTTG
Arginosuccinate lyase Asl Forward : GAGGTGCGGAAGCGGATCAATGT 233
Reverse: TTGGTGCAGTAGAGGATGAGGTCC
Arginosuccinate synthetase Ass Forward: TCGTGCATCCTCGTGTGGCTGAA 157
Reverse: CCACAAACTCCCTGCTGACATCC
ATP synthase 5 subunit e Atp5g1 Forward: TTCCAGACCAGTGTTGTCTCC 146
Reverse: GACGGGTTCCTGGCATAGC
ATP synthase 8 ATP8 Forward: AACAAGTGCTCCATCAATGGC 146
Reverse: AGGCTGGGGTCCCAAAATAAG
Carbamoyl-phosphate synthetase 1 Cps1 Forward: GGCCATCCATCCTCTGTTGC 171
Reverse: GCTAAGTCCCAGTTCATCCA
C-X-C chemokine receptor type 4 Cxcr4 Forward: CCTATGCAAGGCAGTCCATGT 86
Reverse: GGTAGCGGTCCAGACTGATGA
Cytochrome P450, family 2, subfamily C, polypeptide
19
Cyp2C19 Forward: TCCAGATATGCAATAATTTTCCCAC 164
Reverse: GAAGCAATCAATAAAGTCCCGA
Cytochrome P450, family 3, subfamily A, polypeptide 4 Cyp3A4 Forward: CAGGAGGAAATTGATGCAGTTTT 78
Reverse:
GTCAAGATACTCCATCTGTAGCACAGT
Forkhead box A2 FoxA2 Forward: ATTGCTGGTCGTTTGTTGTG 169
Reverse: TACGTGTTCATGCCGTTCAT
Glyceraldehyde 3-phosphate dehydrogenase GAPDH Forward: CAGAACATCATCCCTGCCTCTAC 251
Reverse: TTGAAGTCAGAGGAGACCACCTG
GATA binding protein 4 Gata4 Forward: CTAGACCGTGGGTTTTGCAT 275
Reverse: TGGGTTAAGTGCCCCTGTAG
Hepatocyte nuclear factor 4α HNF4α Forward: TGTCCCGACAGATCACCTC 121
Reverse: CACTCAACGAGAACCAGCAG
N-acetylglutamate synthase Nags Forward: CAGCAGGGCGTATCCAGTC 180
Reverse: GTTGTGTCGAAGCGCGTCTA
NADH dehydrogenase subunit 1 ND1 Forward: TTCTAATCGCAATGGCATTCCT 109
Reverse: AAGGGTTGTAGTAGCCCGTAG
NADH dehydrogenase subunit 5 ND5 Forward: TTCATCCCTGTAGCATTGTTCG 154
Reverse: GTTGGAATAGGTTGTTAGCGGTA
Octamer-binding transcription factor 4 Oct4 Forward: AGCGAACCAGTATCGAGAAC 142
Reverse: TTACAGAACCACACTCGGAC
Ornithine carbamoyltransferase Otc Forward: AATCTGAGGATCCTGTTAAACAATG 106
Reverse: CCTTCAGCTGCACTTTATTTTGTAG
Mitochondrial-specific DNA polymerase gamma Polg Forward: GCTGCACGAGCAAATCTTCG 163
Reverse: GTCCAGGTTGTCCCCGTAGA
Mitochondrial-specific DNA polymerase gamma 2 Polg2 Forward: GCTTAGCCGGGATTCTCTTCT 98
Reverse: CCGAGGTCCACCATTCTGC
Sex determining region Y box 17 Sox17 Forward: GTGGACCGCACGGAATTTG 94
Reverse: GGAGATTCACACCGGAGTCA
Mitochondrial transcription factor A Tfam Forward: ACCGAGGTGGTTTTCATCTG 218
Reverse: TATATACCTGCCACTCCGCC
Mitochondrial uncoupling protein 2 Ucp2 Forward: ATGTTGCTCGTAATGCCATTGT 104
Reverse: GCAAGGGAGGTCATCTGTCA
199Human Hepatocyte-Like Cells for Cell Therapythen replaced with fresh pre-warmed media, and cells were
visualized using a confocal microscope LSM 510 (Zeiss,
Germany, Axiovert 100M).Count of mitochondria number
Transmission electron microscopy (TEM) was used to
investigate the morphological features of the mitochondrial
200 Y. Yu et al.network within differentiated and undifferentiated cells. Cells
were fixed in Trumps solution, sectioned, and imaged by TEM in
the Microscopy Core Facility (Mayo Clinic, Rochester, MN).
Mitochondria numbers were quantified by manually counting
the number of mitochondria per cell. A minimum of 12 cells
were examined in 4–6 representative TEM images (80,000-fold
magnification).
Mitochondrial DNA copy number by quantitative polymer-
ase chain reaction (QPCR)
Copy number of mitochondrial DNA (mtDNA) was esti-
mated by QPCR analysis using the mitochondrial gene NADH
dehydrogenase subunit 1 (ND1) and ND5. Total cellular DNA
was collected and amplified. ND1 and ND5 levels were nor-
malized to half the level of GAPDH since each cell contains two
copies of genomic DNA compared to a single copy of DNA per
chromosome. Each sample was run in triplicate, and QPCR
analysis was performed as described above. Primer sequences
are reported in Table 1.
Quantification of albumin, AFP, ammonia,
ureagenesis, diazepam metabolism
On days 0, 8, 13, 18, and 23 of differentiation culture and day 1
of human hepatocyte culture, old medium was exchanged with
fresh William's E medium supplemented with 10% fetal bovine
serum (FBS; Mediatech, Inc., Herndon, VA), 20 μM diazepam
and 5% v/v heavy deuterium-enriched ammonia gas (15ND3)
(2.23 mM; Cambridge Isotope Laboratories, Inc, Andover, MA).
Cells were incubated for an additional 24 h. Supernatant
medium was collected and stored at −20 °C prior to analysis.
The concentration of human albumin in the sampled medium
was determined by enzyme-linked immunosorbent assay
(ELISA) kit (Bethyl, Montgomery, TX, #E80-129). The concen-
tration of human AFP was determined in the Automated
ImmunoAssay Laboratory of the Mayo Division of Clinical
Biochemistry and Immunology. The concentration of total
urea was performed using a QuantiChromTM DIUR-500 Urea
Assay Kit (BioAssay System, Hayward, CA) according to the
manufacturer’s instructions. Production of urea through the
complete urea cycle was determined by the conversion of
heavy ammonia (15ND3) to native and deuterium-enriched urea.
Isotopes of urea were quantified by capillary gas chromatogra-
phy/mass spectrometry as previously reported (Rinaldo, 2008).
Concentrations of diazepam and its three major metabolites
(nordiazepam, temazepam, oxazepam) were determined by
high performance liquid chromatography (HPLC) with mass
spectrometry detection in the CTSA Metabolomics Core lab at
Mayo Clinic (Baskin-Bey et al., 2005; Mandrioli et al., 2008).
Samples were deconjugated in β-glucuronidase/arylsulfatase
(600 Fishman units and 4800 Roy units/mL, respectively;
Roche, Indianapolis, IN) and sodium acetate buffer (0.1 M) for
2 h. Reactions were quenched with ethanol. Data acquisition
was completed by Chrom Perfect® software (Denville, NJ). All
assays were performed in triplicate.
Oxygen consumption
Rates of oxygen consumption were determined by syringe
technique as previously reported (Lillegard et al., 2011).
Briefly, cells were resuspended in 3 mL of culture mediumand oxygen tensions of the medium were determined at 2 min
intervals over 6 min by a GEM Premier 3000 gas analyzer.
The rate of oxygen consumption was determined using the
equation:
Oxygen consumption molO2=minð Þ
¼ pO2: initial mmHg– pO2: final mmHgð Þ
 1:29 109molO2=mL=mmHg
 
 volumemlð Þ= timeminð Þ
Statistical analysis
Data are expressed as mean±standard deviation of indepen-
dent samples. Comparisons between two groups were per-
formed by unpaired Student's t-test. p-Values≤0.01 were
considered significant. Data were analyzed by SPSS 16 and
Excel 2003, Microsoft, Redmond, WA.
Results
Generation HLCs from hiPSCs
The morphology of hiPSCs changed significantly from day
0 to day 23 during four stages of differentiation. The light
microscopic appearance of representative cultures of hiPSCs
(day 0), endoderm (day 8), hepatic specific (day 13),
hepatoblast (day 18), HLCs (day 23), and primary human
hepatocytes are shown in Fig. 1A. hiPSCs gradually trans-
formed into less dense, flatter cells with prominent nuclei
and spiky shape (day 8) before eventually forming an
epithelial monolayer on day 23. Other features of HLCs
included a large cytoplasmic-to-nuclear ratio, numerous
and prominent nucleoli, and occasional binucleated cells.
These features were also characteristic of primary hepato-
cytes (Fig. 1A).
To confirm the differentiation status of cells during the
four stages ofmaturation we examined the relative expression
of 22 genes using QRT-PCR analyses. These genes included the
pluripotency marker (OCT4) and four endoderm markers
(FOXA2, GATA4, CXCR4, SOX17) shown in Fig. 1B. Expression
of three liver-related genes (HNF4α, AFP, Alb) are shown in
Fig. 2A. Expression of the six urea cycle genes (Nags, Cps1,
Otc, Ass, Asl, Arg1) were included in Fig. 4A because of their
importance to ammonia detoxification and their therapeutic
role in cell therapy of liver failure. Expression of CYP3A4 and
CYP2C19, whose protein products are important phase 1
enzymes, are shown in Fig. 5A. Expression of Atp5g1, Atp8,
Ucp2, Tfam, Polg, Polg2 (Fig. 6A) were used to assess mito-
chondrial differentiation.
As expected, loss of the pluripotency marker OCT4 was
observed during the 4 stages of differentiation as shown in
Fig. 1B. Expression of the four endoderm genes shown in
Fig. 1B was significantly higher on day 8 and at all later time
points compared to hiPSCs (day 0).
To further assess the differentiation of hiPSCs, we
performed immunofluorescence staining (Fig. 1C). All of
the undifferentiated hiPSCs expressed the pluripotency
marker OCT4 on day 0. By day 8, end of the S1, a sharp
decline in OCT4 staining and a rapid rise in the number of
cells staining positive for the definitive endoderm marker
Figure 1 Generation of HLCs from hiPSCs. A. Cell morphology
by light phasemicroscopy. The cells gradually transformed into less
dense, flatter layers with prominent nuclei (S1), a spiky shape, and
then formed an epithelial monolayer (S4). HLCs with large
cytoplasmic-to-nuclear ratio, numerous, and prominent nucleoli
were observed on day 23, which were of similar morphology and
character to primary hepatocytes. B. Relative expression of early
stage genes of differentiation. The early stage of hiPSCs differen-
tiation was characterized by the loss of pluripotency marker OCT4.
All of the other genes were expressed significantly higher at day 23
(HLCs) than at day 0 (hiPSCs). The special markers for different
stages of differentiation (GATA4 for S1, HNF4α for S2, AFP for S3
and Alb for S4) confirmed the successful differentiation of
hiPSCs to HLCs. C. Immunofluorescence staining of human cells
during 4 stages (23 days) of differentiation. Human hepato-
cytes are included for comparison (far right column).
Figure 2 Characteristics of the HLCs. A. Relative expression
of three hepatocyte-related genes using QRT-PCR analyses. Day
23 HLCs expressed higher levels of AFP RNA and lower levels of
Alb mRNA than the primary hepatocytes. B. Accumulation of
albumin and AFP in the culture supernatant were consistent
with expression of these genes in iPS cells (day 0), HLCs (day 23)
and hepatocytes. No human albumin was detected in medium
of day 0 cultures, which confirmed specificity of our human
albumin ELISA. Data are represented as mean±standard devia-
tion. C. Immunofluorescence staining for AFP and Alb. On day 23
most HLCs stained positively for AFP and Alb, while human
hepatocytes only stained positively for Alb.
201Human Hepatocyte-Like Cells for Cell TherapyGATA4 was observed. This pattern of staining suggested
efficient differentiation of iPSCs to endoderm. By day 13,
end of S2, HNF4α stained cells were observed. HNF4α is
believed to be essential for specification of hepatic pro-
genitors from human pluripotent stem cells (DeLaForest et
al., 2011). By day 18, end of S3, the addition of hepatocyte
growth factor (HGF) to the culture conditions resulted in
high levels of expression of AFP, and indicated that the
specified cells had committed to a hepatoblast fate. By day
23, end of S4, remaining cells stained brightly for albumin
that could be quantified in the media by ELISA (Fig. 2B). On
average, 80% of the day 23 cells were Alb-positive (Fig. 2C).
On day 23, after completion of the differentiation protocol,
the cells were found to display several known hepatic
functions. PAS staining (Fig. 3) indicated glycogen synthesis
by the differentiated cells. Analyses of the culture media
revealed the ability of day 23 cells to secrete albumin (Fig. 2B),
produce urea (Fig. 4B), and metabolize diazepam (CYP3A4 and
CYP2C19 enzyme activities) (Fig. 5B).
We also examined the mitochondria to assess differentia-
tion of hiPSCs to HLCs (Fig. 6). Cell ultrastructure by TEM
demonstrated that undifferentiated hiPSCs on day 0 possessed
Figure 3 PAS staining for glycogen synthesis. Left—hiPSCs stained very weakly positive for PAS on day 0. Middle—HLCs stained
positively for PAS on day 23. A focus of less differentiated cells that do not stain for PAS is shown in the upper center of the image.
Primary hepatocytes uniformly stain positive for PAS.
Figure 4 Expression of urea cycle genes and ureagenesis. A.
The QRT-PCR assay of urea cycle genes. HLCs expressed lower
mRNA level of urea cycle genes than the primary hepatocytes.
B. Hepatoblasts (day 18) and HLCs (day 23) showed the ability to
produce urea. However, the concentration of urea in these
cultures was significantly lower than cultures of primary hepato-
cytes (pb0.01). Furthermore, the formation of heavy urea from
heavy ammonia was only demonstrated by primary hepatocytes,
indicating that only primary hepatocytes were capable of normal
ureagenesis. Data are represented as mean±standard deviation.
202 Y. Yu et al.the fewest number and smallest size of mitochondria
(Fig. 6C). On day 0, mitochondria were round-shaped, had
poorly developed crista, and were located near the nucleus.
As hiPSCs lost pluripotency and committed to a hepatic
differentiation fate, the expression of mtDNA transcription
and replication factors was upregulated (Fig. 6A). The
number of mitochondria/cell (Fig. 6D) and mtDNA copies/
cell (Fig. 6B) also increased as cells lost pluripotency. With
differentiation, both cells and their mitochondria increased in
size. The ultrastructural features ofmitochondria also became
more mature (Fig. 6C). Maturing mitochondria acquired an
elongated morphology with swollen cristae and dense matri-
ces as they migrated into wider cytoplasmic areas. Concom-
itantly, the rate of oxygen consumption by differentiated cells
increased (Fig. 6E) as aerobic metabolism became active and
more efficient. Collectively, these observations were consis-
tent with successful production of HLCs from hiPSCs.
Human HLCs vs. primary human hepatocytes
Higher AFP and lower albumin by HLCs
To test whether HLCs can provide functionality to ex vivo
cell therapies, such as a BAL, we compared the extent of
differentiation of HLCs to primary human hepatocytes. We
first compared the relative gene expression of Alb and AFP in
HLCs and human hepatocytes using QRT-PCR. The results
reveal that HLCs expressed a high level of albumin mRNA, but
this level was still lower than the level in primary hepatocytes
(Fig. 2A). Consistentwith this difference in gene transcription,
we observed significantly higher concentrations of albumin in
the supernatant of cultures of primary hepatocytes compared
to HLCs (Fig. 2B). In contrast, primary hepatocytes expressed
low levels of AFP mRNA compared to HLCs (Fig. 2A). No AFP
was detected in supernatant of primary hepatocytes (Fig. 2B)
and primary human hepatocytes did not stain for AFP by
immunocytochemistry (Fig. 2C). Cultures of HLCs expressed
high levels of AFP mRNA (Fig. 2A) and secreted high levels of
AFP into the medium (Fig. 2B). Interestingly, most HLCs
stained positively for AFP by immunocytochemistry (Fig. 2C).
An inverse relationship was observed between the expres-
sion pattern of AFP and Alb in HLCs. These findings suggest
Figure 5 CYP3A4 activity and diazepam metabolism. A.
Expression of CYP3A4 and CYP2C19 increased significantly during
the 4 stages of differentiation and was greatest in primary human
hepatocytes. ND—expression of CYP3A4 was not detectable in
hiPSCs. B. Clearance of diazepam and formation of its threemajor
metabolites (nordiazepam, temazepam, oxazepam) was highest
in cultures of primary hepatocytes (pb0.01), indicating greater
phase 1 metabolism by primary hepatocyte than HLCs (day 23) or
iPSCs (day 0). Data are represented as mean±standard deviation.
203Human Hepatocyte-Like Cells for Cell Therapydifferences between HLCs and primary hepatocytes, con-
sistent with a less mature phenotype of HLCs than primary
hepatocytes.Incomplete urea cycle activity by HLCs
Compared to primary hepatocytes, day 23 HLCs expressed
lower levels of mRNA of the urea cycle genes (Fig. 4A). The
HLCs showed an ability to produce urea (Fig. 4B). However,
this level of production was significantly lower than primary
hepatocytes. More importantly, neither hiPSCs nor HLCs
were able to produce heavy urea when heavy ammonia
(15ND3) was supplemented to their culture (Fig. 4B). In
contrast, over 40% of urea contained heavy isotopes after
the culture medium of primary hepatocytes was supple-
mented with heavy ammonia (Fig. 4B). These data indicated
urea cycle activity is complete in primary hepatocytes, but
incomplete in less mature cells such as HLCs and iPSCs. The
urea formed in cultures of HLCs and iPSCs likely represented
the activity of its final step (i.e., arginase), rather than activity
of the complete urea cycle.Lower CYP activity by HLCs
The CYP enzymes are critical enzymes of phase 1 metabo-
lism. In particular, CYP3A4 is normally abundant in human liver.
Of little surprise, expression of CYP3A4 genewas not detectable
in hiPSCs, and rose steadily during the four stages of
differentiation (Fig. 5A). However, CYP3A4 expression did not
reach the level of primary hepatocytes. Functionality of the CYP
enzymes was assessed by the elimination of the classical
substrate, diazepam, and appearance of its major metabolites
(temazepam, nordiazepam, and oxazepam). Temazepam is a
marker of 3-hydroxylation by CYP3A4; nordiazepam is a marker
of N-dealkylation by CYP2C19; and oxazepam is the product
of both CYP activities. Therefore, Fig. 5B demonstrates
significantly higher CYP3A4 and CYP2C19 activity by primary
hepatocytes than HLCs. The higher concentrations of nordia-
zepam in cultures of HLCs and primary hepatocytes suggest
that CYP2C19 is the major pathway of diazepam elimination
by both cell types. The low level of diazepam elimination in
cultures of hiPSCs suggests non-specific loss of drug since no
major metabolites were detected in its supernatant.
Immature mitochondria and lower oxygen consumption by
HLCs
Because of their role in energy production and therefore
functionality of hepatocytes, mitochondria were a focus of
our analysis. Mitochondria were assessed in terms of gene
expression (Fig. 6A), replication (Figs. 6B and D), ultra-
structure (Fig. 6C), and respiration (oxygen consumption,
Fig. 6E). Replication of mtDNA is regulated by the nuclear-
encoded mitochondrial transcription factor A (TFAM) and
the mitochondrial-specific DNA polymerase gamma (POLG),
which consists of a catalytic (POLG1) and an accessory
(POLG2) subunit. Our QRT-PCR showed that both Polg and
Tfam were expressed at baseline (day 0) and during the
steps of differentiation. Expression of Tfam declined during
differentiation, while expression of the five othermitochondrial
genes (Polg, Polg2, Ucp2, Atp5g, Atp8) was increased (Fig. 6A).
Consistent with the rise inmitochondrial gene expression during
differentiation, mtDNA copy number increased 50-fold from
hiPSCs to HLCs (Fig. 6B). Mitochondrial number per cell and
mtDNA copy number were highest in primary hepatocytes
(Figs. 6B and D). The difference in maturity of HLCs vs. primary
hepatocytes was further uncovered by the ultrastructural
features and redox status of their mitochondria (Fig. 6C).
Consequently, oxygen consumption by primary human hepato-
cytes was significantly higher than human HLCs (Fig. 6E).
Discussion
Access to an abundant, high quality supply of hepatocytes
with therapeutic potential for cell transplantation and ex-
tracorporeal support of patients in liver failure has been the
objective of several research programs. Though hepatic
differentiation of hiPSCs has been described (Chen et al.,
2012), the functionality of HLCs derived from hiPSCs remains
poorly studied in the context of primary human hepatocytes
or their application in cell based therapies. The Fox group
has reported an implantable BAL device containing HLCs
derived from embryonic stem cells (ESCs) in a murine model
of liver failure (Soto-Gutierrez et al., 2006). However, no
reports have addressed functionality of HLCs derived from
Figure 6 Mitochondrial features during differentiation of hiPSCs to hepatocytes. A. Expression of Polg, Polg2, Ucp2, Atp5g1 and Atp8
role steadily during stages of differentiation, while expression of Tfamdeclined over this time frame. B. The ratio ofmitochondrial DNA to
nuclear DNA rose significantly (pb0.01) during differentiation reflecting the robust expansion of mitochondria in differentiating cells.
ND1 and ND5 are genes encoded on mitochondrial DNA. Data are represented as mean±standard deviation. C. Top row—cells were
examined by confocal microscopy using MitoTracker Red to assess their expanding density of functional mitochondria (red stain) during
stages of differentiation. Nuclei were stained blue by DAPI. Middle row (Low power TEM) and Lower Row (high power TEM)—mitochondria
were observed to elongate, develop swollen cristae and dense matrices, and migrate deeper into the cytoplasm during stages of
differentiation. The mitochondria of HLCs (day 23) appeared less mature than the mitochondria in primary hepatocytes. D. Mitochondria
were counted from TEM images. The number of mitochondria rose steadily through stages of differentiation and reached a maximum in
primary hepatocytes. The number of mitochondria in HLCs (day 23) was significantly less than in primary hepatocytes (pb0.01). Data are
represented as mean±standard deviation. E. The level of oxygen consumption by HLCs (day 23) was significantly lower than primary
hepatocytes (pb0.01). Data are represented as mean±standard deviation.
204 Y. Yu et al.hiPSCs in a cell-based BAL. Our results show a characteristic
polygonal epithelial morphology and large cytoplasm of HLCs
derived from hiPSCs. These HLCs contained cytoplasmic
granules of hepatocytes and expressed hepatocyte-specific
genes. Additionally, HLCs exhibited known functions of maturehepatocytes, such as albumin production and the appearance
of urea in culture medium. We also observed CYP activity
and PAS staining consistent with glycogen storage by HLCs.
Collectively, these observations confirm the generation of
HLCs from hiPSCs.
205Human Hepatocyte-Like Cells for Cell TherapyTo address the question of whether these HLCs could serve
in cellular therapies, a variety of markers of hepatocyte dif-
ferentiation were considered. For example, production of
albumin, a classic marker of hepatocyte differentiation, was
observed in HLCs (Fig. 2). However, production of albumin has
been shown to be non-predictive of response to cell-based
therapy (Dunn et al., 1991; Koike et al., 1996; Nahmias et al.,
2007). Alternatively, mitochondria play a crucial role in many
cellular functions relevant to cell based therapy including
energy production, differentiation, apoptosis, and ammonia
detoxification. Mitochondria are the site of several enzymes of
the urea cycle and thus essential to ammonia detoxification
and prevention of hepatic encephalopathy. Our data indicate
significant maturation of mitochondria in HLCs compared to
their hiPSCs precursors. However the mitochondria of HLCs
remain noticeable lessmature than the gold standard - primary
hepatocytes.
Our experience with hiPSCs and HLCs is analogous to the
maturation of ESCs. Reviewed evidence suggests that respira-
tory activity in mitochondria of ESCs is low to minimize
generation of reactive oxygen species which may damage and
mutate DNA during early development (Parker et al., 2009). As
stem cells of the early embryo commit to differentiation, their
mitochondria undergo dramatic functional maturation. Suc-
cessful differentiation of mammalian ESCs involves transcrip-
tion and replication of the mtDNA genome, replication of
mitochondria, and up-regulation of enzymes required for
aerobicmetabolism (Chen et al., 2008; Cho et al., 2006; Chung
et al., 2007; Schieke et al., 2008; Suhr et al., 2010). These
changes are needed to fulfill the elevated ATP requirements of
fully differentiated cells. In the case of primary hepato-
cytes, they are rich in mitochondria to fulfill their many
vital roles including metabolism, synthesis of blood proteins
and biotransformation. Our results suggest that HLCs derived
from hiPSCs are capable of many of these functions, but they
do not appear to detoxify ammonia to urea under ex vivo
conditions.
Our results also demonstrate that cultured HLCs express
higher levels of AFP and lower levels of albumin than human
hepatocytes produced by in vivo expansion in genetically
engineered mice (Azuma et al., 2007). Our observations are
similar to other reports of significant but lower than normal
production of albumin by HLCs (Cai et al., 2007; Sancho-Bru et
al., 2011; Si-Tayeb et al., 2010; Song et al., 2009). The high
levels of AFP production in HLCs are unexplained, but suggest
that HLCs exhibit an inability to turn off early stage gene(s) as
the mechanism of persistent immature phenotype.
As mentioned above, the liver is a major site of detoxifica-
tion, and ammonia is arguably the most important endogenous
toxin which requires clearance by the liver (Denis et al., 1983).
Ammonia accumulation causes cerebral edema, the most
feared complication of acute liver failure (Haussinger et al.,
1992). A functioning urea cycle must be present for ammonia to
be effectively detoxified and eliminated from the body (Ytrebo
et al., 2009). Therefore, ammonia removal and urea production
are important considerations for ex vivo cell therapies. Our data
indicate that HLCs are inferior to primary hepatocytes at both
ammonia detoxification and ureagenesis. The CYP enzymes,
found in high levels in the human liver, are also important to
detoxification of endogenous and exogenous wastes. Our HLCs
expressed high levels of mRNA from CYP3A4 and CYP2C19 and
detectable CYP3A4 andCYP2C19 enzymeactivity. However, theCYP activities of HLCs were significantly below that of primary
human hepatocytes.
Mitochondria play a vital role in the balance between
pluripotency, cellular differentiation, and replication
(Armstrong et al., 2010). TFAM, POLG and POLG2 are the
key genes in regulating mtDNA replication. All three genes
are nuclear-encoded, but produce transcription factors
which are translocated to the mitochondria. We observed
that the expression of POLG and POLG2 increased progressively
in hiPSCs, HLCs, and primary hepatocytes; however, expression
of TFAM declined with maturity. Our data is consistent with
reports that an increase in the number of TFAM molecules
above the optimal mtDNA:TFAM stoichiometry has inhibitory
effects on mtDNA transcription and replication (Garstka et al.,
2003; Webb and Smith, 1977). Therefore, a reduction in levels
of TFAM protein may explain, in part, the increased transcrip-
tion of mtDNA through the 4 stages of differentiation (Kanki et
al., 2004).
Mammalian mitochondria are composed of approximately
1000 different proteins, but only 13 proteins are encoded by
the mitochondrial genome. We selected Atp5g, Atp8 and
Ucp2 as protein markers of the mitochondrial genome. We
observed progressively higher expression of Ucp2, Atp5g and
Atp8 in hiPSCs, HLCs, and primary hepatocytes. It has hitherto
been believed that the ratio of mtDNA to nuclear DNA reflects
the tissue concentration of mtDNA per cell. Control of mtDNA
copy number is crucial for successful differentiation of ESCs
(Facucho-Oliveira et al., 2007), and presumably also of hiPSCs.
With the hepatic differentiation of hiPSCs, we observed an
increased mtDNA copy number. MitoTracker staining also
rose to reflect the expanded number of mitochondria in the
cytoplasm during hepatic differentiation.
Our hiPSCs were derived from human cardiac fibroblasts.
These parental fibroblasts possessed a large supply of mito-
chondria. However, reduction and dedifferentiation of mito-
chondria was essential for proper energy production and for
prevention of DNA damage by oxidative stress in their con-
version to hiPSCs. In turn, re-differentiation of hiPSCs to HLCs
involved resupplying mitochondrial mass to meet the elevated
ATP requirements of differentiated hepatocytes (Brown, 1992).
It is possible that the difference in maturity profile and
functionality between our HLCs and primary hepatocytes can
be explained by our original source of somatic cells, the cardiac
fibroblasts. Prior work with hiPSCs derived from fibroblasts
suggests that mitochondrial numbers returned to their pre-
reprogrammed state or lower levels after re-differentiation
(Armstrong et al., 2010; Suhr et al., 2010). Whether the lower
mitochondrial functionality of our HLCs was due to their cell of
origin is unknown. Alternatively, the mitochondrial comple-
ment of HLCs may require more time and more replicative
cycles to realize its full potential (Suhr et al., 2010). Further
work is needed to clarify the role of original somatic cell type
and other factors in re-programming iPSCs to new mature cell
types.Conclusion
In conclusion, our results confirm that functional HLCs can
be generated from hiPSCs. However, our studies suggest that
HLCs produced in vitro are not sufficiently mature to serve
as ex vivo cell therapies, such as an extracorporeal BAL. Our
206 Y. Yu et al.results support those of Takayama et al. (2012), and suggest
that a more native milieu is needed to complete hepatic
differentiation of HLCs. Other reports suggest that in vivo
transplantation of HLCs derived from hiPSCs can rescue
rodents from lethal drug-induced acute liver failure (Chen et
al., 2012), reduce liver fibrosis in a mouse model (Asgari et
al., in press), enhance liver regeneration in mice (Espejel et
al., 2010), and stabilize chronic liver disease (Choi et al.,
2011). These in vivo studies suggest that novel techniques
are still needed to complete hepatic differentiation of HLCs
and expand them in numbers sufficient for human therapy.
One possibility for expansion and maturation of HLCs is a
genetically engineered large animal, similar but larger than
the source of human hepatocytes in our study (Azuma et al.,
2007), to serve as an in vivo hepatocyte incubator (Hickey et
al., 2011). The future success of ex vivo cell therapies
depends on novel techniques to provide an abundant, high
quality supply of functionally normal hepatocytes.Acknowledgements
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